Posttransplant Malignancy.

@article{Rossi2019PosttransplantM,
  title={Posttransplant Malignancy.},
  author={Ana P. Rossi and Christina L. Klein},
  journal={The Surgical clinics of North America},
  year={2019},
  volume={99 1},
  pages={
          49-64
        }
}
Posttransplant malignancy is a leading cause of death after solid organ transplantation (SOT). Recipients of SOT are at significantly higher risk of multiple cancers compared with the general population, most notably nonmelanoma skin cancer and posttransplant lymphoproliferative disorders. Risk factors for posttransplant malignancy include history of malignancy, immunosuppression, oncogenic viral infections, sun exposure, and disease-specific associations. Early detection and treatment of… 
5 Citations
Hematologic malignancies of the gastrointestinal luminal tract
TLDR
In this article, common and rare hematologic malignancies of the GI tract are reviewed and their pathophysiologic, clinical, and imaging features are discussed.
Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword?
TLDR
This work reviews the published cases and suggests feasible approaches for renal transplant patients with advanced malignancy treated by a PD-1 inhibitor, mammalian target of rapamycin (mTOR) inhibitors and anti-VEGF may act as regulators of tumor-specific and allogenic T-cells.
Propensity-Matched Survival Analysis of Upper Urinary Tract Urothelial Carcinomas between End-Stage Renal Disease with and without Kidney Transplantation
TLDR
The oncologic outcome of UTUC after KT is poor in this observation, even after propensity scored-matched analysis, which indicates the immunosuppression status is still associated with more malignant UTUC behavior.
Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota
TLDR
This review will attempt to dissect some of the studies demonstrating cancer immunotherapy modulation by specific gut microbes and discuss possible molecular mechanisms for this effect.

References

SHOWING 1-10 OF 104 REFERENCES
De Novo Malignancies After Transplantation: Risk and Surveillance Strategies.
TLDR
Risk factors and outcomes of frequently encountered de novo malignancies after liver and kidney transplantation are summarized to stratify recipients at highest risk to improve survival of these complex patients.
Genitourinary Malignancies in Solid Organ Transplant Recipients
TLDR
The major genitourinary malignancies and their management will be reviewed in this article with emphasis on the concerns that arise in a transplant recipient.
Malignancy after Transplantation
TLDR
Although calcineurin inhibitors and azathioprine have been linked with posttransplant malignancies, newer agents such as mycophenolate mofetil and sirolimus have not and indeed may have antitumor properties and long-term data are needed to determine if the use of these agents will ultimately lower the mortality due to malignancy for transplant recipients.
Skin cancers after organ transplantation.
TLDR
This review discusses the epidemiology, pathogenesis, and management of squamous-cell and basal-cell carcinomas, cancers of the anogenital region, Kaposi's sarcoma, melanoma, neuroendocrine skin carcinoma, and cutaneous manifestations of lymphoma in transplant recipients.
Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients
  • J. Krisl, V. Doan
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2017
TLDR
The role of immunosuppression in cancer and to review the classes of chemotherapeutics are explained and information on class review, adverse effects, dose adjustments, and drug interactions that are pertinent to the care of transplant recipients is provided.
Cancer in the transplant recipient.
TLDR
A review of each of the issues as they come to affect transplantation: cancer before wait-listing, cancer transmission from the donor, cancer after transplantation, outcomes of transplant recipients after a diagnosis of cancer, and the role of screening and therapy in reducing the impact of cancer in transplant recipients are provided.
Immunosuppressant-Driven De Novo Malignant Neoplasms after Solid-Organ Transplant
TLDR
Reducing levels of immunosuppressant drug levels to as low as possible for healthy engraftment and altering regimens when appropriate are management strategies that could lessen this complication of solid-organ transplant.
Cancers complicating organ transplantation.
  • I. Penn
  • Medicine
    The New England journal of medicine
  • 1990
TLDR
Analysis of 5250 tumors that occurred in 4933 patients reported to the Cincinnati Transplant Tumor Registry (CTTR), a worldwide data base, reveals many striking findings.
Daunting but Worthy Goal: Reducing the De Novo Cancer Incidence After Transplantation
TLDR
It is essential to manage the recipient with a long-term adapted screening program beginning before transplantation to use a prophylaxis to decrease infection-related cancer, to propose a viral monitoring, and to modulate the immunosuppression toward lower doses especially for calcineurin inhibitors.
Post-transplant lymphoproliferative disorders
Post-transplant lymphoproliferative disorders (PTLDs) are a group of conditions that involve uncontrolled proliferation of lymphoid cells as a consequence of extrinsic immunosuppression after organ
...
1
2
3
4
5
...